Full text is available at the source.
Abstract
Lipid nanoparticles (LNPs) have enabled the successful delivery of nucleic acid-based vaccines and therapeutics, exemplified by the COVID-19 mRNA vaccines and Onpattro.
- Advances in lipid-based systems have addressed the challenge of delivering genetic information to target cells in vivo.
- Clinically approved examples of LNPs include mRNA vaccines for COVID-19 and the small interfering RNA therapeutic Onpattro for amyloidosis.
- Ongoing clinical development includes various promising LNP-enabled vaccines and gene therapies.
- The success of LNPs is linked to research on lipoplexes with positively charged lipids and the use of ionizable cationic lipids in LNP design.
- Insights from these research streams may provide delivery solutions for a wide range of gene therapies.
Simplified